AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims

- 1-23. (Canceled)
- 24. (New) A method for treating a bacterial infection in a human in need thereof, the method comprising:

administering initial and subsequent therapeutically effective doses of dalbavancin in a pharmaceutically acceptable carrier to the patient,

wherein each dose is separated by five to ten days and wherein the amount of the initial dose is about 500 mg to about 5000 mg and the amount of each subsequent dose is about 250 mg to about 2500 mg.

- 25. (New) The method of claim 24, the method comprising administering a single subsequent dose.
- 26. (New) The method of claim 25, wherein the subsequent dose is administered about one week after the initial dose without any intervening dose of dalbavancin.
- 27. (New) The method of claim 24, the method comprising administering multiple subsequent doses.
- 28. (New) The method of claim 27, wherein said subsequent doses are administered at about one week intervals without any intervening doses of dalbavancin.

2

Attorney Docket: 892,280-137

- 29. (New) The method of claim 24, wherein the bacterial infection is a skin and soft tissue infection.
- 30. (New) The method of claim 29, wherein the bacterial infection is a complicated skin and soft tissue infection.
- 31. (New) The method of claim 29, wherein the bacterial infection is an uncomplicated skin and soft tissue infection.
- 32. (New) The method of claim 24, wherein the amount of the initial dose is about 1500 mg.
- 33. (New) The method of claim 24, wherein the amount of the initial dose is about 1000 mg.
- 34. (New) The method of claim 24, wherein the amount of the initial dose is about 800 mg.
- 35. (New) The method of claim 24, wherein the amount of the initial dose is about 500 mg.
- 36. (New) The method of claim 24, wherein the amount of each subsequent dose is about 400 mg to about 1000 mg.
- 37. (New) The method of claim 24, wherein the amount of each subsequent dose is about 500 mg.

3

- 38. (New) The method of claim 24, wherein the amount of each subsequent dose is about 400 mg.
- 39. (New) The method of claim 24, wherein the amount of each subsequent dose is about 250 mg.
- 40. (New) The method of claim 24, wherein the amount of each subsequent dose is about 200 mg.
- 41. (New) The method of claim 24, wherein the amount of the initial dose is about 1000 mg and the amount of each subsequent dose is about 250 mg.
- 42. (New) A method for treating a bacterial infection in a human in need thereof, the method comprising:

administering initial and subsequent therapeutically effective doses of dalbavancin in a pharmaceutically acceptable carrier to the patient,

wherein each dose is separated by five to ten days and wherein the amount of the initial dose is about 200 mg to about 1500 mg and the amount of each subsequent dose is about 200 mg to about 1500 mg.

- 43. (New) The method of claim 42, the method comprising administering a single subsequent dose.
- 44. (New) The method of claim 43, wherein the subsequent dose is administered about one week after the initial dose without any intervening dose of dalbavancin.

- 45. (New) The method of claim 42, the method comprising administering multiple subsequent doses.
- 46. (New) The method of claim 45, wherein said subsequent doses are administered at about one week intervals without any intervening doses of dalbavancin.
- 47. (New) The method of claim 42, wherein the bacterial infection is a skin and soft tissue infection.
- 48. (New) The method of claim 47, wherein the bacterial infection is a complicated skin and soft tissue infection.
- 49. (New) The method of claim 47, wherein the bacterial infection is an uncomplicated skin and soft tissue infection.
- 50. (New) The method of claim 42, wherein the amount of the initial dose is about 1500 mg.
- 51. (New) The method of claim 42, wherein the amount of the initial dose is about 1000 mg.
- 52. (New) The method of claim 42, wherein the amount of the initial dose is about 800 mg.
- 53. (New) The method of claim 42, wherein the amount of the initial dose is about 500 mg.

- 54. (New) The method of claim 42, wherein the amount of each subsequent dose is about 400 mg to about 1000 mg.
- 55. (New) The method of claim 42, wherein the amount of each subsequent dose is about 500 mg.
- 56. (New) The method of claim 42, wherein the amount of each subsequent dose is about 400 mg.
- 57. (New) The method of claim 42, wherein the amount of each subsequent dose is about 250 mg.
- 58. (New) The method of claim 42, wherein the amount of each subsequent dose is about 200 mg.
- 59. (New) The method of claim 42, wherein the amount of the initial dose is about 1000 mg and the amount of each subsequent dose is about 250 mg.